Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ramat Gan
Clinical trial register · Israel

Clinical Trials in Ramat Gan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2438 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2438
Studies in scope
all four open statuses
1243
Recruiting now
open to new participants
461
Lead sponsors
across recruiting studies
Top sites
Jerusalem 52 Haifa 49 Ramat Gan 43 Petah Tikva 40 Kfar Saba 39
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC86 AbbVie67 Janssen Research & Development, LLC50 AstraZeneca43 Sheba Medical Center30 Clear sponsor filter
Site location
Jerusalem52 Haifa49 Ramat Gan43 Petah Tikva40 Kfar Saba39
All 21 locations
Target enrolment
to

Trials with a site in Ramat Gan

43 of 2438 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
AstraZeneca
Phase 2
24
Haifa, Kfar Saba, Petah Tikva, Ramat Gan
2026-08-31
Recruiting
AstraZeneca
Phase 3
7,000
Ashkelon, Be’er Ya‘aqov, Hadera, Haifa, Holon, Kfar Saba, Nahariya, Ramat Gan
2026-08-21
Recruiting
AstraZeneca
Phase 3
670
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2026-05-04
Recruiting
AstraZeneca
Phase 2
435
Ashkelon, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2025-11-06
Recruiting
AstraZeneca
Phase 3
800
Ashdod, Hadera, Haifa, Holon, Jerusalem, Nahariya, Ramat Gan, Safed
2025-08-01
Recruiting
AstraZeneca
Phase 3
830
Afula, Beersheba, Hadera, Haifa, Jerusalem, Ramat Gan, Tel Aviv
2025-04-10
Recruiting
AstraZeneca
Phase 2
540
Haifa, Jerusalem, Kfar Saba, Ramat Gan, Rehovot
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Ashkelon, Haifa, Jerusalem, Kfar Saba, Ramat Gan, Rehovot, Tel Aviv
2025-03-25
Recruiting
AstraZeneca
Phase 3
11,300
Beersheba, Be’er Ya‘aqov, Haifa, Herzelia, Holon, Jerusalem, Petah Tikva, Ramat Gan
2025-03-14
Active, closed
AstraZeneca
Phase 3
768
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2024-10-04
Recruiting
AstraZeneca
Phase 3
788
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2024-08-01
Recruiting
AstraZeneca
Phase 3
240
Afula, Haifa, Jerusalem, Kfar Saba, Ramat Gan
2024-06-20
Active, closed
AstraZeneca
Phase 3
2,554
Ashkelon, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2024-03-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nahariya, Ramat Gan, Jerusalem, Tel Aviv
2023-12-20
Active, closed
AstraZeneca
Phase 3
314
Afula, Haifa, Jerusalem, Kfar Saba, Ramat Gan
2023-11-08
Active, closed
AstraZeneca
Phase 3
1,835
Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot
2023-11-07
Active, closed
AstraZeneca
Phase 3
5,511
Afula, Haifa, Jerusalem, Kfar Saba, Nahariya, Ramat Gan
2023-10-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Haifa, Ramat Gan
2023-06-05
Recruiting
AstraZeneca
Phase 3
4,300
Afula, Ashdod, Haifa, Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Rehovot
2023-03-31
Active, closed
AstraZeneca
Observational
551
Kfar Saba, Tel Hashomer, Tiberias, Haifa, Jerusalem, Afula, Ramat Gan, Tel Aviv
2023-02-27
Recruiting
AstraZeneca
Phase 3
3,527
Afula, Ashkelon, Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan
2022-12-13
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Petah Tikva, Ramat Gan, Tel Aviv
2022-05-23
Active, closed
AstraZeneca
Phase 3
1,035
Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2022-03-25
Active, closed
AstraZeneca
Phase 3
315
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan
2021-06-30
Active, closed
AstraZeneca
Phase 3
1,157
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2021-04-26
Active, closed
AstraZeneca
Phase 3
358
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2020-12-16
Active, closed
AstraZeneca
Phase 3
185
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2020-08-04
Active, closed
AstraZeneca
Phase 3
866
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin
2020-07-13
Active, closed
AstraZeneca
Phase 3
818
Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Ashkelon, Beersheba, Jerusalem, Ramat Gan, Rehovot, Tel Aviv
2019-10-29
Active, closed
AstraZeneca
Phase 3
724
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2019-03-06
Active, closed
AstraZeneca
Phase 3
1,063
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2018-11-16
Active, closed
AstraZeneca
Phase 3
1,246
Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2018-09-27
Active, closed
AstraZeneca
Phase 2
528
Haifa, Kfar Saba, Petah Tikva, Ramat Gan
2017-12-18
Active, closed
AstraZeneca
Phase 3
987
Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan
2017-03-27
Active, closed
AstraZeneca
Phase 1/2
264
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2016-03-17
Active, closed
AstraZeneca
Phase 3
953
Beersheba, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin
2015-11-02
Active, closed
AstraZeneca
Phase 3
682
Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv
2015-10-21
Active, closed
AstraZeneca
Phase 3
1,837
Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Haifa, Kfar Saba, Ramat Gan
2013-09-03
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 October 2026. https://priyalifescience.com/clinical-trials-israel/city/ramat-gan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,438 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Ramat Gan that also match the filters currently applied.

How many clinical trials are recruiting in Ramat Gan?

15 of the 43 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ramat Gan), 43 studies
PhaseStudiesRecruitingShare
Phase 3341079.1%
Phase 2439.3%
Observational317%
Phase 1/2214.7%

Most active sponsors

Lead sponsors with the most studies (Ramat Gan)
Lead sponsorStudiesRecruiting
AstraZeneca4315
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.